AFP — AFT Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- AU$273.81m
- AU$305.70m
- NZ$156.64m
- 87
- 27
- 48
- 56
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 85.1 | 106 | 113 | 130 | 157 |
Cost of Revenue | |||||
Gross Profit | 40.7 | 48.3 | 48.7 | 61.8 | 73 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 79 | 84.4 | 102 | 110 | 137 |
Operating Profit | 6.12 | 21.2 | 10.7 | 20.4 | 19.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.26 | 12.9 | 7.89 | 18.7 | 15.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.43 | 12.7 | 7.78 | 19.8 | 10.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.43 | 12.7 | 7.78 | 19.8 | 10.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.36 | 11.7 | 7.59 | 19.8 | 10.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.035 | 0.021 | 0.074 | 0.19 | 0.102 |